Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy in Non-Asian Patients

Abstract

Intravitreal ranibizumab was well tolerated in non-Asian patients with polypoidal choroidal vasculopathy; the majority of eyes experienced improvements in best-corrected visual acuity and center point thickness after ranibizumab treatment.

Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

“…This phenomenon has been found by several studies. [19223435363738394041] Lai et al . [34] reported the efficacy of intravitreal bevacizumab therapy for PCV.…”

“…Using ranibizumab (as-needed) therapy, Marcus et al . [38] reported that the mean BCVA increased from baseline by 1.2 Snellen lines at 12 and 24 months. The mean CRT decreased by 53 and 67 μm from baseline at 12 months and 24 months, respectively.…”

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population

“…Our previous study 7 showed good results with ranibizumab 0.5 mg and overall supports anti-VEGF monotherapy as a viable therapy for non-Asian PCV. The majority of patients with baseline CFT 4300 μm had favorable vision gains and CFT reduction.…”

“…[4][5][6][7][8][9][10][11][12][13][14] In a previous study 7 (ClinicalTrials.gov identifier: NCT00837330), we evaluated intravitreal ranibizumab 0.3-and 0.5-mg monotherapy in 20 eyes of non-Asian patients with PCV. Ranibizumab (0.3-and 0.5-mg groups pooled) was well tolerated and resulted in improved best-corrected visual acuity (BCVA; +1.2 Snellen lines at months 12 and 24) and reduced center point thickness (−53 and − 67 μm at months 12 and 24, respectively) in the majority of eyes.…”

Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience

“…The rate of complete regression in polyps was found to be 77.8% with combined treatment, 71.4% with PDT monotherapy, and 28.6% with ranibizumab monotherapy (6,19) A mean of 5 injections were performed in the present study. In a study conducted by Marcus et al (24), a mean of 7.2 injections per eye was administered over a 24-month follow-up period. They observed a 1.2 Snellen letter-increase at month 24 compared with the baseline.…”